Multiple studies have demonstrated that urokinase plasminogen activator (uPA) and plasminogen activator inhibitor-1 (PAI-1) have clinical utility as breast cancer biomarkers. uPA is an extracellular matrix-degrading protease involved in cancer invasion and metastasis. PAI-1 is thought to enhance angiogenesis and block apoptosis. Although PAI-1 inhibits the activity of uPA, very high levels of these two […]